# Vejledning til ansøgningsskema for fritagelse for bilateral margin for ikke clearede OTC-derivater:

|  |  |  |
| --- | --- | --- |
| **Entry Field** | **Details** | **Relevant Regulering** |
| A1-A5 |  |  |
| A6 |  | *Article 2(8-9) EMIR* |
| A7 |  | *Article 39 RTS 2016/2251* |
| B1 |  | *Article 3 EMIR* |
| B2 | This description should satisfy the requirements laid down in EMIR OTC answer 6. Note that supporting documentation must be provided under the Entry Field “G2”. | *Article 3 EMIR* |
| B3 |  | *Article 11(6-10) paragraph a EMIR* |
| B4 | Provide a description. |  |
| C1-C4 |  | *Article 11(5-10) paragraph b EMIR.*  *Article 33 and 34 RTS 2016/2251* |
| D1-D6 |  |  |
| D7 | If the ITG counterparty is both a Financial Counterparty or a Non-Financial Counterparty and a Third Country Entity, select the entry “Third Country Entity” | *Article 2(8-9) of EMIR* |
| E1-E2 | Select the exemption for which you wish to apply/notify |  |
| E3 |  | *Article 18(1) paragraph b RTS 149/2013* |
| E4 | If for instance the IGT counterparty is a FC established in Sweden, the relevant NCA to name would be “Finansinspektionen”. |  |
| E5 |  | *Article 3(3) paragraph a EMIR* |
| E6 | Describe how the applicant counterparty and the intragroup counterparty are included in the same consolidations in accordance with Article 3(3)(a) of EMIR |  |
| E7 |  | *Article 3(3) paragraph a EMIR* |
| E8-E9 |  |  |
| F1-F9 |  | *Article 18 RTS 149/2013* |
| G1-G4 |  | *Article 18(2) RTS 149/2013* |
| H1-H4 |  |  |